Thymogen: research

A Russian peptide used for immune problems, with negative cancer trials.

Also called: Timogen, Thymagen, L-Glu-L-Trp, Glu-Trp, EW, Alpha-glutamyl-tryptophan, Oglufanide, IM862, IM-862.

Khavinson bioregulator peptides · Synthetic L-glutamyl-L-tryptophan immune-modulating dipeptide.

Controlled IM862 cancer trials found no clear benefit. The 59 human records include trial registrations, incomplete reports and stomach studies that reuse participants.

Studies

• Kaposi sarcoma: two nasal schedules. rct, n=44, Adults with AIDS-related Kaposi sarcoma; 39/44 used protease inhibitors. Early responses were not confirmed in the later placebo-controlled trial. (source)
• Kaposi sarcoma: negative phase 3. rct, n=202, HIV-positive adults with Kaposi sarcoma. IM862 did not beat placebo and may have accelerated progression. (source)
• Kidney cancer: no tumor responses. single-arm, n=25, Adults with metastatic renal cell carcinoma. High nasal doses produced no objective cancer responses. (source)
• Prostate cancer: no clear benefit. rct, n=71, Men with rising PSA after prostate surgery and/or radiation. IM862 did not prolong time to PSA progression. (source)
• Before abdominal cancer surgery. rct, n=127, Older adults undergoing abdominal or retroperitoneal cancer surgery. Fewer complications were reported, with important reporting errors. (source)
• Skin and soft-tissue wound trial. rct, n=77, Adults aged 18–55 with moderate skin or soft-tissue infections. A small blinded trial reported faster wound healing. (source)
• Severe multiple injuries. rct, n=327, People with severe mechanical polytrauma. The report suggests fewer complications, without usable numerical effect estimates. (source)
• Oral gel: stomach biopsy findings. rct, n=116, Adults with H. pylori-associated chronic atrophic gastritis. Biopsy changes favored oral gel; clinical importance remains uncertain. (source)
• Oral gel: endoscopy subset. rct, n=80, Subset with active inflammation from the atrophic gastritis program. A selected subgroup had improved endoscopy scores. (source)
• Oral gel: inflammation counts. rct, n=116, Adults aged 40–76 with H. pylori-associated atrophic gastritis. Inflammation markers improved after oral gel. (source)
• Oral gel: stomach blood markers. rct, n=116, Same 116-person atrophic gastritis program. Some blood markers changed; symptom and cancer benefits remain unproven. (source)
• Uterine cancer surgery. cohort, Women with uterine cancer. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Spinal bone infection. case-series, n=54, Patients aged 15–76 with nonspecific spinal osteomyelitis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Diabetic eye disease. cohort, Patients with diabetic retinopathy. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Acute pancreatitis. cohort, n=48, 48 acute pancreatitis patients; 36 healthy donors. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Infected soft-tissue wounds. case-series, n=31, Patients with purulent wounds. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Destructive pulmonary tuberculosis. cohort, Patients receiving tuberculosis medicines. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Tuberculosis immune-drug comparisons. cohort, n=553, Patients with destructive pulmonary tuberculosis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Noncancer bile-duct blockage. cohort, n=105, Three jaundice groups: 28, 35 and 42 patients. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Childhood chronic tonsillitis. cohort, Children with chronic tonsillitis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Cataract surgery with uveitis. case-report, n=1, One patient with sympathetic uveitis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Pancreatitis immune-guided care. cohort, n=63, People with different acute pancreatitis forms. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Periodontal bone material. cohort, n=66, People with chronic generalized periodontitis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Salivary-gland inflammation. cohort, Patients with sialoadenitis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Childhood laryngeal papillomas. cohort, n=39, Children with recurrent laryngeal papillomatosis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Type 1 diabetes with immune deficits. cohort, People with type 1 diabetes and secondary immune deficiency. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Oral candidiasis. case-series, n=52, Patients with candidiasis of the mouth. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Hepatitis B follow-up. cohort, n=500, Patients followed after acute hepatitis B. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Bronchial asthma. cohort, Patients with bronchial asthma. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Pelvic inflammation at a health resort. cohort, n=225, Women of reproductive age. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Complicated gallstones. cohort, Surgical gallstone patients; animal work also reported. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Pelvic inflammation and fertility. cohort, Women receiving health-resort therapy. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Gonorrhea and chlamydia. cohort, Patients receiving pefloxacin with immune therapy. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Tuberculosis immune-cell mobility. cohort, 35 active TB patients, 128 previously cured people, 30 healthy controls. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Chronic suppurative bronchitis. cohort, n=33, Patients with chronic suppurative obstructive bronchitis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Radiation-related immune deficits. cohort, n=100, 100 patients plus a separate 160-animal experiment. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Respiratory infections in soldiers. cohort, Members of a military training unit. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Chronic bacterial skin infections. case-series, n=23, Patients with chronic pyoderma. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Pelvic inflammatory disease. case-series, n=46, Women with uterine or adnexal inflammatory disease. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Jaw and head injury with bone infection. cohort, n=42, Patients with post-traumatic osteomyelitis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Recovery after severe cold exposure. case-series, Survivors of the Komsomolets submarine accident. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Skin sarcoidosis: no benefit. cohort, n=28, People with skin sarcoidosis. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Drug-resistant bacterial skin infections. cohort, n=126, 126 patients screened; 23 received a Thymogen course. The report is too incomplete to define a dependable dosing or benefit estimate. (source)
• Childhood COVID-19: combination medicine. cohort, n=132, Children aged 1–17 with COVID-19: 52 on Cytovir-3 versus 27 on umifenovir; exposed family contacts: 28 on Cytovir-3 versus 25 untreated.. Separate retrospective treatment and prevention comparisons evaluated a three-component medicine. (source)
• Childhood respiratory infections: combination trial. rct, n=90, Children aged 2–6 with acute respiratory infections. These data concern a three-component medicine. (source)
• Workers exposed to chemical waste. cohort, n=249, 249 exposed workers aged 18–63; separate 137-worker control group. Selected workers reported fewer illnesses after immune therapy. (source)
• Oral gel: four case examples. case-series, n=4, Four clinical cases of H. pylori or autoimmune atrophic gastritis. Small uncontrolled observations cannot prove recovery of stomach tissue. (source)
• Oral gel: autoimmune gastritis. single-arm, n=10, 10 adults aged 33–72 enrolled; 9 completed two courses at interim analysis. Small uncontrolled observations cannot prove recovery of stomach tissue. (source)
• Oral gel: autoimmune gastritis case. case-report, n=1, One patient with autoimmune atrophic gastritis. Small uncontrolled observations cannot prove recovery of stomach tissue. (source)
• Oral gel after H. pylori therapy. case-report, n=1, One adult with H. pylori-associated atrophic gastritis. Small uncontrolled observations cannot prove recovery of stomach tissue. (source)
• Vaccination plus combination medicine. cohort, n=283, People at increased respiratory infection risk. A combination medicine was associated with fewer respiratory illnesses. (source)
• Respiratory prevention: three groups. cohort, n=340, People at increased respiratory infection risk. A combination medicine was associated with fewer respiratory illnesses. (source)
• Combination medicine: immune-marker review. meta-analysis, Four controlled reports published in 2018–2021. A combination review does not establish Thymogen-alone efficacy. (source)
• Ovarian cancer: dose escalation. single-arm, n=43, Ovarian Cancer. 43 enrolled; completed, without posted results. (source)
• Colon cancer: stopped trial. rct, n=18, Colorectal Cancer. 18 enrolled; terminated because the drug was unavailable. (source)
• Ovarian combination: status unknown. rct, Ovarian Cancer. Status unknown; 180 was projected accrual, not a verified enrollment. (source)
• Rat lifespan and tumors. animal, n=76, Female outbred rats. Mean lifespan did not increase; selected survival and tumor measures improved. (source)
• Natural killer cells in mice. animal, Tumor-bearing mice with selected gene or immune-cell defects. Mouse antitumor effects depended on natural killer cell function. (source)
• Inflammation signals in cultured cells. in-vitro, Human leukemia-derived THP-1 cells, not treated people. Cell effects do not establish immune benefit in people. (source)
• Dose-dependent effects in blood cells. in-vitro, Cultured human peripheral blood lymphocytes. Higher concentrations can suppress cell growth in vitro. (source)
• Childhood recurrent wheeze: nasal trial. rct, n=86, Children aged 4 months to 6 years with recurrent airway obstruction during respiratory infections. A small pediatric study reported fewer respiratory episodes after a nasal course. (source)
• Oral gel: stomach acidity. rct, n=116, Adults aged 40–76 with H. pylori-associated chronic atrophic gastritis. Stomach acidity measures improved; this is another report from the same 116-person program. (source)
• Hepatitis C: stopped dose-escalation plan. open-label, Adults aged 18–60 with chronic hepatitis C; target 32, actual enrollment not supplied. Registry says stopped early; no results or actual doses received were verified. (source)

Gaps: Human-study count describes human report and registry records, not independent trials or proven exposures. Several indexed reports do not establish who received Thymogen. The 116-person gastritis program generated several papers and an 80-person subset. Old pyoderma reports may share 23 treated patients. Many older Russian reports lack accessible full texts, exact arms, numerical outcomes or adverse-event rates. An exhaustive non-indexed literature census is not established. The surgery paper’s English abstract says 100 mg; Russian text says 100 mcg. Its complication percentages also conflict with the reported denominators. The tuberculosis abstract prints a 1% solution. Its concentration was not confirmed; no usable dosing protocol was created from it. PubMed asthma and nearby records have misattached abstracts. Asthma arm sizes and effects were not imported from the mismatched records. Prostate, ovarian and colorectal IM862 dose amounts or results remain incomplete. Three registry-only records have no posted results. The published nasal cancer regimens cannot define a maximum safe injected dose or validate community injection schedules. No numeric subcutaneous human dose ceiling was verified. aboveStudied=false on the community SC record means unclassifiable, not within a known safe range. No controlled longevity, thymus-regrowth, long-COVID or ME/CFS efficacy study was verified for Thymogen alone. The oral gel is a distinct formulation. Capsule absorption, identity and equivalence to gel or nasal dosing are unknown. No validated immune-marker target, wellness-monitoring schedule, long-term safety limit or reproductive washout interval was found. Direct interactions with insulin, sulfonylureas, anticoagulants and oral contraceptives were not established. This is not proof of no interaction. Combination-formulation studies cannot isolate Thymogen effects; four underlying reports in the 2025 meta-analysis were not all independently retrieved. No validated home bacteriostatic-water recipe, mixed-vial lifetime or common vial-size survey was verified. Community prevalence describes this search, not population frequency. nMentions counts distinct people or experiments, not repeated comments. FDA 503A eligibility is explicitly restricted, but nomination history, category placement, 503B status and a Thymogen-specific PCAC vote remain unverified. EU national approvals, UK/Canadian complete database exclusions and Australian poison-schedule coverage remain incompletely verified. No compound-specific WADA ruling was found. Russian therapeutic registration prevents simply assuming S0 from lack of FDA approval. The pediatric nasal RCT was retrieved, but older book, conference and combination-study reports remain incomplete. No pediatric protocol is supplied. The 2022 gastric pH paper has a printed DOI that did not resolve. The original paper and national medical-library record were checked instead. ACTRN12606000505505 planned SC cohorts from 0.5 mcg to 50 mg and one 5 mg inhaled cohort. The stopped trial has no verified results or actual exposure; these are not dosing protocols. A separate intranasal HCV program was mentioned in secondary reports; its primary registry and results were not located.

Related to Thymogen

• Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
• Pinealon: A peptide with unproven brain benefits and no established injection dose.
• Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
• Vesugen: An experimental blood-vessel peptide with unclear benefits and poorly defined safety.
• Cortagen: A four-amino-acid brain peptide backed mainly by animal work and unverified patent claims.
• BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.

Thymogen: the short version

Sources

• Bulk Drug Substances Used in Compounding, FDA · 2026
• Medicines, European Medicines Agency · European Medicines Agency · 2026
• MHRA Products | Home, MHRA · MHRA · 2026
• Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
• TGA warning on the risks of importing unapproved peptide products, Therapeutic Goods Administration · 2026
• The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
• Darmerica, LLC - 716152 - 12/08/2025, FDA · FDA · 2025
• Инструкция по медицинскому применению лекарственного препарата Регастим Гастро, Министерство здравоохранения Российской Федерации · 2023
• Тимоген р-р для в/м инъекций - Цитомед - инструкция по применению, 2023
• Тимоген спрей - Цитомед - инструкция по применению, 2011
• Тимоген: крем для наружного применения. Инструкция по медицинскому применению препарата, 2007
• Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
• Drug Product Database online query
• OGLUFANIDE SODIUM
• Alpha-glutamyl-tryptophan as adjuvant reparative therapy after Helicobacter pylori eradication in chronic atrophic gastritis: A case report and literature review, 2026

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.